5PSQ-063 Efficacy and safety of benralizumab in severe eosinophilic asthma in a tertiary hospital

<h3>Background and Importance</h3> Asthma is a chronic airway inflammatory disease that affects more than 300 million people worldwide. Approximately a quarter of these patients have severe eosinophilic asthma, characterised by the presence of eosinophils in bronchial biopsies and sputum. In the last few years, monoclonal antibodies such as mepolizumab, benralizumab, reslizumab or tezepelumab have been approved for its treatment. <h3>Aim and Objectives</h3> To assess effectiveness and security of monoclonal antibody benralizumab for the treatment of severe eosinophilic asthma in real-life in a tertiary hospital. <h3>Material and Methods</h3> Observational, descriptive and retrospective study carried out between July 2017 and September 2024, including adult patients treated with benralizumab for at least 1 year in a tertiary hospital. Variables included: age, sex, duration of treatment, eosinophil count, number of exacerbations, daily oral corticosteroid dose, and adverse effects associated with treatment. Data were extracted from digital medical records and in hospital electronic prescribing and they were analysed with the statistical program IBM SPSS statistics version 29.0.2.0. <h3>Results</h3> Forty-four patients were included: female 88.6% (n=39) median of 55 years-old (rank 37–84). The median follow-up duration of the treatment was 30.3 months. The mean blood eosinophil count before the start of treatment was 549.0 ± 342.5 eosinophils/μl, and 11.8 ± 33.4 eosinophils/μl after treatment. There was a mean of 1.8 ± 2.2 exacerbations in the year before treatment and 0.3 ± 0.9 exacerbations in the year after. Eighteen patients were taking daily corticosteroids before treatment, reducing this to 14 after treatment. A total of 14 patients (31.3%) experienced adverse reactions associated with treatment, all of which were mild. <h3>Conclusion and Relevance</h3> Benralizumab showed a significant reduction in eosinophil levels, the rate of exacerbations and the need for daily oral corticosteroids after treatment. In terms of safety, it has a moderate incidence of adverse effects. Therefore, it appears to be effective and safe. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest